Pharmaceutical drugs – Scuba Dive Talks http://scubadivetalks.com/ Tue, 21 Sep 2021 17:02:36 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://scubadivetalks.com/wp-content/uploads/2021/07/scuba.png Pharmaceutical drugs – Scuba Dive Talks http://scubadivetalks.com/ 32 32 USask and City of Saskatoon researchers find drug and chemical concentrations in wastewater treatment plant – archyworldys https://scubadivetalks.com/usask-and-city-of-saskatoon-researchers-find-drug-and-chemical-concentrations-in-wastewater-treatment-plant-archyworldys/ https://scubadivetalks.com/usask-and-city-of-saskatoon-researchers-find-drug-and-chemical-concentrations-in-wastewater-treatment-plant-archyworldys/#respond Tue, 21 Sep 2021 16:26:53 +0000 https://scubadivetalks.com/usask-and-city-of-saskatoon-researchers-find-drug-and-chemical-concentrations-in-wastewater-treatment-plant-archyworldys/ For the first time, research was conducted on the presence of pharmaceuticals in the Saskatoon Wastewater Treatment Plant (WWTP) and in the South Saskatchewan River (SSR). The study was led by USask’s principal investigator, Dr Markus Brinkmann (PhD) of School and Environment and Sustainability, and the director of the city’s sewage treatment plant. from Saskatoon, […]]]>

For the first time, research was conducted on the presence of pharmaceuticals in the Saskatoon Wastewater Treatment Plant (WWTP) and in the South Saskatchewan River (SSR). The study was led by USask’s principal investigator, Dr Markus Brinkmann (PhD) of School and Environment and Sustainability, and the director of the city’s sewage treatment plant. from Saskatoon, Mike Sadowski. The research was conducted with plant operators, who told researchers that this type of systematic research has never been done before.

While their research originally focused on the level of pharmaceuticals in Saskatoon’s wastewater, their research also provided revealing results on how the initial lockdown due to COVID-19 affected the city. Even though effluent levels were high enough to pose a risk to aquatic organisms, the pharmaceuticals measured, such as pain relievers, antiepileptics, beta blockers, and antibiotics, were unlikely to pose a toxicological risk to them. organisms living in the SSR after dilution. in the river water. In addition, industrial chemicals, illicit drugs, dyes and human drug metabolites have been detected using screening tests. These include methamphetamine, insecticides and dyes for fabrics and plastics.

“These results provide important information, as pressures on our freshwater resources are expected to increase due to various factors driven in large part by climate change,” said Brinkmann. “The need to protect these increasingly sensitive freshwater ecosystems will only be evident. “

Brinkmann’s team conducted research on Saskatoon’s wastewater throughout 2020, with a grant supported by Research Junction. Research Junction is a collaboration between the City of Saskatoon and Research Acceleration and Strategic Initiatives to support the development of joint research projects that address contemporary urban issues for the benefit of the residents of Saskatoon.

“Currently, there are no regulations for pharmaceutical contaminants under Canada’s Wastewater Systems Effluent Regulations, nor any restriction in the provincial permit under which the plant. sewage treatment works, ”Sadowski said. “However, the city is taking action to protect and conserve the South Saskatchewan River by partnering with Professor Brinkmann’s team in this regard.

Brinkmann said the results of their study will serve as a benchmark for future efforts focused towards decision-making regarding the need for future mitigation of these pharmaceutical chemicals.

Next steps for the team include reviewing processes to help reduce these chemicals in the effluent process. They will also study how pharmaceuticals affect the sludge in the wastewater treatment plant, which is stabilized and applied to agricultural land as a fertilizer.

Asked about the Research Junction Discovery Grant program, Brinkmann said, “The most important aspect of the program is financial support to facilitate collaborative projects between the university and municipal partners. These types of partnerships are crucial for conducting applied research that can lead to real results for city partners and direct benefits for Saskatoon residents.

This joint wastewater treatment project between the USask and the city has been praised for its achievements. In particular, the project was recognized by the Smart 50 Awards, which recognize innovative and influential work improving the quality of life of residents at the municipal level.

]]>
https://scubadivetalks.com/usask-and-city-of-saskatoon-researchers-find-drug-and-chemical-concentrations-in-wastewater-treatment-plant-archyworldys/feed/ 0
Amneal Pharmaceuticals Inc., H. Lundbeck AS, Mylan NV – Stillwater Current https://scubadivetalks.com/amneal-pharmaceuticals-inc-h-lundbeck-as-mylan-nv-stillwater-current/ https://scubadivetalks.com/amneal-pharmaceuticals-inc-h-lundbeck-as-mylan-nv-stillwater-current/#respond Tue, 21 Sep 2021 03:32:08 +0000 https://scubadivetalks.com/amneal-pharmaceuticals-inc-h-lundbeck-as-mylan-nv-stillwater-current/ The report published on Orthostatic Hypotension Drugs Market: By Diagnostic Test Type (ECG, Blood Tests, Stress Test, and Others), Drug Type (Midodrine, Northera (droxidopa), Fludrocortisone, Caffeine, and Others) and End User ( hospitals, ASCs and clinics and others) Comprehensive Analysis and Forecast of Global Industry Outlook, 2019-2025 market by Zion Market Research provides a better […]]]>

The report published on Orthostatic Hypotension Drugs Market: By Diagnostic Test Type (ECG, Blood Tests, Stress Test, and Others), Drug Type (Midodrine, Northera (droxidopa), Fludrocortisone, Caffeine, and Others) and End User ( hospitals, ASCs and clinics and others) Comprehensive Analysis and Forecast of Global Industry Outlook, 2019-2025 market by Zion Market Research provides a better understanding of current market opportunities, revenue growth, and trends. The report aims to offer qualitative and quantitative analysis of the market dynamics and opportunities prevailing over the forecast period. Furthermore, the report includes in-depth study of major Orthostatic Hypotension Drugs market leaders.

FREE | Sample request is available @ https://www.zionmarketresearch.com/sample/orthostatic-hypotension-drugs-market

Global Orthostatic Hypotension Drugs Market: Competitive Players Amneal Pharmaceuticals Inc., H. Lundbeck AS, Mylan NV, Novartis AG and Pfizer Inc., among others.

The research report includes the outline of the global Orthostatic Hypotension Drugs market such as definition, classifications, and applications. Apart from that, it involves the complete assessment of a number of factors such as restraints, opportunities, drivers, challenges and risks. Further, the global Orthostatic Hypotension Drugs market is divided on the basis of various parameters into respective segments and sub-segments. The report also encompasses the existing, previous and probable growth trends in the market for each segment and sub-segment. In addition, the market is also segregated on the basis of North America, Europe, Asia-Pacific, and Latin America regions. along with a detailed assessment of their growth, key developments and strategies, opportunities and key models influencing the market expansion in these regions. The report will also include a special part highlighting the changes and the ongoing COVID-19 pandemic. It includes in-depth market analysis based on the predictions of post-COVID-19 market circumstances along with data on existing impacts on the Pandemic Orthostatic Hypotension Drugs market.

Promising Regions & Countries Mentioned In The Orthostatic Hypotension Drugs Market Report:

  • North America (United States)
  • Europe (Germany, France, United Kingdom)
  • Asia-Pacific (China, Japan, India)
  • Latin America (Brazil)
  • The Middle East and Africa

Download the Free PDF Report Brochure @ https://www.zionmarketresearch.com/requestbrochure/orthostatic-hypotension-drugs-market

The research report also highlights the wide range of tactical stages, such as latest business transactions, joint ventures, partnerships, mergers and acquisitions, technology developments, and launch of new products brought to market. Further, it examines several models of the global Orthostatic Hypotension Drugs market, involving the rules, criteria, and policy deviations implemented by private companies and government in the market over the past few years. Finally, the analysis includes forecast and historical data, making it a valuable asset for experts, industry leaders, presentations, sales and product managers, consultants and any other person or organization. looking for essential market data and statistics.

Key details and USP of the existing report study:

  • Global Orthostatic Hypotension Drugs Market Size Market Size by Volume (K Units) and Value (USD Million) for Historical Period (2016 – 2019) and Projected Years (2020 – 2026)
  • Regionally (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) Orthostatic Hypotension Drugs Market Size by Volume (K Units) and Value (USD Million) ) for the historical period (2016 – 2019) and projected years (2020 – 2026)
  • Market size at country level (US, Canada, Germany, UK, France, Spain, Italy, China, Japan, India, South Korea, Southeast Asia, Brazil, Mexico, GCC, Africa South, RoW) of Orthostatic Hypotension Drugs Market by Volume (K Units) and Value (USD Million) for Historical Period (2016 – 2019) and Projected Years (2020 – 2026)
  • Market size type divided into its individual product type (concentration, temperature, combustion, conductivity and others) in terms of volume (K units) and value (USD Million) for historical period (2016 – 2019) and years projected (2020 – 2026))
  • Demand side and supply side perspective and analysis
  • Market share of companies / actors / manufacturers / suppliers / service providers
  • Analysis of the competitive landscape, the competition matrix and the positioning of the players
  • Market dynamics, trends, factors affecting the growth of the market in the coming year
  • Analysis of key buyers and end users
  • Value chain and supply chain analysis, including distribution and sales channels, as well as upstream and downstream integration scenarios
  • Analysis of the manufacturing cost structure
  • Analysis of key raw materials
  • Key pricing strategies adopted in the market
  • Key marketing strategies adopted in the market
  • Porters Five Forces Analysis
  • SWOT analysis
  • PESTLE analysis

Request an impact analysis of the coronavirus on sectors and the market Learn more about this report @ https://www.zionmarketresearch.com/inquiry/orthostatic-hypotension-drugs-market

What the reports provide

  • Complete and in-depth analysis of the parent market
  • Significant changes in market dynamics
  • Market segmentation details
  • Old, ongoing and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of the main players
  • Emerging segments and regional markets
  • Testimonials from companies to strengthen their presence in the market.

In addition, the research report examines:

  • Competitors and manufacturers in the world market
  • By product type, applications & Growth factors
  • Industry status and outlook for Main applications / End users / Field of use

Thank you for reading this article; you can also get a section by chapter or a report version by region, such as North America, Europe or Asia.

]]>
https://scubadivetalks.com/amneal-pharmaceuticals-inc-h-lundbeck-as-mylan-nv-stillwater-current/feed/ 0
The stock market is collapsing. These 5 actions are not. https://scubadivetalks.com/the-stock-market-is-collapsing-these-5-actions-are-not/ https://scubadivetalks.com/the-stock-market-is-collapsing-these-5-actions-are-not/#respond Mon, 20 Sep 2021 17:23:00 +0000 https://scubadivetalks.com/the-stock-market-is-collapsing-these-5-actions-are-not/ Text size Covid-19 vaccine Scott Olson / Getty Images Fears of contagion in the indebted Chinese real estate market sent U.S. markets tumbling on Monday as investors pulled back from some of the riskier stocks. But while some stocks have suffered their worst blow in weeks, a few companies have ignored the general malaise and […]]]>

Text size

]]>
https://scubadivetalks.com/the-stock-market-is-collapsing-these-5-actions-are-not/feed/ 0
Health Experts Discuss High Drug Prices And Potential For Reform At Virtual Penn Event https://scubadivetalks.com/health-experts-discuss-high-drug-prices-and-potential-for-reform-at-virtual-penn-event/ https://scubadivetalks.com/health-experts-discuss-high-drug-prices-and-potential-for-reform-at-virtual-penn-event/#respond Mon, 20 Sep 2021 05:18:51 +0000 https://scubadivetalks.com/health-experts-discuss-high-drug-prices-and-potential-for-reform-at-virtual-penn-event/ One of the panelists, scientist Mariana Socal, said about one in four Americans struggled to afford drugs. Credit: Jesse Zhang Penn’s Leonard Davis Institute of Health Economics hosted a virtual seminar where panelists discussed high drug prices and opportunities for reform in the current political climate. The seminar, entitled “Drug Pricing: Policy and Politics”, brought […]]]>

One of the panelists, scientist Mariana Socal, said about one in four Americans struggled to afford drugs. Credit: Jesse Zhang

Penn’s Leonard Davis Institute of Health Economics hosted a virtual seminar where panelists discussed high drug prices and opportunities for reform in the current political climate.

The seminar, entitled “Drug Pricing: Policy and Politics”, brought together Benedic Ippolito, senior researcher at the American Enterprise Institute, Rachel Sachs, professor of law at the University of Washington, and Mariana Socal, scientist at Johns Hopkins Bloomberg School of Public Health. The event was moderated on Friday by Perelman School of Medicine and Wharton School professor Rachel Werner.

Speakers began the discussion by agreeing that while there is an extraordinary need to tackle high drug prices in the United States, reforms have stalled and been insufficient for years. Socal cited the statistic that about one in four Americans struggle to afford drugs and about three in 10 Americans who take prescription drugs said they did not take a prescribed drug as recommended because of the cost.

Sachs categorized current drug pricing reform efforts into three categories: proposals to address high drug costs, proposals discouraging financial incentives for drug companies, and policies targeting underlying high drug prices.

In the political arena, Ippolito said that two main issues need to be addressed: people with illness with available treatment who need to reduce drug prices, and people with illness without available treatment who have need to invent treatments. This forces politicians to prioritize and balance the two issues, Ippolito said.

Ippolito said that since financial incentives are important for those in the private markets who invest in medical innovation, he is confident that the reform will reduce pharmaceutical revenues, but he is not confident in the exact magnitude.

Sachs agreed with Ippolito and took issue with the idea that the direction of drug price reform was one-sided. Instead, she said expanding insurance, either specifically through drug coverage under Medicare drug coverage or the Affordable Care Act, would increase the use of drugs. prescription drugs, increase returns to the pharmaceutical industry and theoretically increase medical innovation.

Panelists also discussed policies to increase access to drugs for the Medicaid and Medicare populations, exploring funding and delivery solutions for hepatitis C treatment Sofosbuvir, marketed as Sovaldi, and the controversial drug. against Alzheimer’s disease Aducanumab, marketed under the name Aduhelm.

Sachs said Sovaldi is the perfect example of a breakthrough drug that treated a disease prevalent among disadvantaged Americans, but states faced a difficult funding problem and were unable to distribute the drug to all. patients. She said states would face a similar problem with Aduhelm, but questions remain about its clinical effectiveness.

Socal added that the Alzheimer’s drug on the market is clouded by its complexity due to its clinical trials and the Food and Drug Administration approval process. She said the problem lies with the state and will require a rebalancing of incentives between states and the federal government.

Panelists also discussed and debated state-level policies, including innovative payment models like a subscription model, or policies aimed at increasing transparency in drug prices for patients. They also discussed insulin – which has tripled in price over the past decade – and how to prevent a similar situation from happening with another drug in the future.

Panelists said that among the intricacies of drug pricing reform, there are definitive solutions that Congress and drug companies can and must adopt, although none will be easily implemented.

“In this complex pricing environment, it’s hard to predict what kinds of tradeoffs and all kinds of effects these policies will have,” Ippolito said.

]]>
https://scubadivetalks.com/health-experts-discuss-high-drug-prices-and-potential-for-reform-at-virtual-penn-event/feed/ 0
Reviews | The economic mistake Democrats are finally facing https://scubadivetalks.com/reviews-the-economic-mistake-democrats-are-finally-facing/ https://scubadivetalks.com/reviews-the-economic-mistake-democrats-are-finally-facing/#respond Sun, 19 Sep 2021 14:00:08 +0000 https://scubadivetalks.com/reviews-the-economic-mistake-democrats-are-finally-facing/ It would be nice to have the Republican Party imagined by the Niskanen Center, a party more focused on access to a decent life at an affordable price than optional vaccination, and I wish them good luck in their efforts to make that happen. White. For now, however, it’s the Democrats who are starting to […]]]>

It would be nice to have the Republican Party imagined by the Niskanen Center, a party more focused on access to a decent life at an affordable price than optional vaccination, and I wish them good luck in their efforts to make that happen. White. For now, however, it’s the Democrats who are starting to take supply-side concerns seriously.

But before I get to that, I want to broaden the definition of “sourcing,” a boring word that looms over exciting possibilities. Progressivism on the supply side should not only solve the problems of the present, it should accelerate the progress of the future. A problem of our time is that there is too little utopian thought, but a worthy exception is Aaron Bastani’s “fully automated luxury communism”, a left-wing leaflet that puts technologies in development right now – intelligence artificial, renewable energy, asteroid extraction, plant and cell – meat-based meats and genetic editing – at the center of a post-work, post-scarcity vision.

“What if everything could change?” ” he asks. “What if, more than just tackling the great challenges of our time – from climate change to inequalities and aging – we go far beyond, putting today’s problems behind us as we did before with the big boys. predators and, for the most part, disease. What if, rather than having no idea of ​​a different future, we decided that the story hadn’t really started? “

Bastani’s vision is invigorating as it emphasizes that those of us who believe in a radically fairer, gentler, and more sustainable world have an interest in delivering the technologies that will make this world possible. It is a political question as much as a technological one: these same technologies could become accelerators of inequalities and desires if they are not integrated into well-thought-out policies and institutions. But what Bastani clearly sees is that the world we should want requires more than redistribution. It requires inventions and advancements that make old problems obsolete and new possibilities multiple.

Climate change is the most pressing example. If the Biden administration gave every American a check to switch to renewables, the policy would fail because we haven’t built as much renewable capacity, let alone the supply chain needed to deploy and maintain it. In a world where two-thirds of emissions now come from middle-income countries like China and India, the only way for humanity to tackle both climate change and poverty is to invent our own way. ” get clean, abundant, cheap energy and then spend enough to deploy it quickly.

Or take health care. House and Senate Democrats are fighting over dueling policies to let Medicare set the prices it pays for drugs. Europeans and Canadians pay much less for the same prescription drugs we buy, so House Democrats want to let Medicare price at least some drugs at 120% of what our peer countries pay. According to STAT, Senate Democrats appear to be moving towards requiring Medicare to set prices based on what the Veterans Health Administration pays, which is lower than before but still higher than overseas . (It is darkly comical that neither House has simply taken the position that Americans should not pay more than Canadians for prescription drugs.)

The counter-argument here is frustrating, but important. Yes, Americans are paying too much compared to peer countries for drugs. But to truly cure, manage or prevent disease is of extraordinary value to humanity. Pfizer and Moderna will make billions from their coronavirus vaccines, but they have created billions of dollars in economic value by thawing savings, not to mention lives saved. It is true that European countries benefit from the high price we pay for drugs, because it is the American market that drives innovation. But that doesn’t mean we’d better pay their prices, if it meant that new drug development was slowing down. We don’t just want everyone to have health insurance in the future. We want them to be healthier; free from diseases and pain that even the best health insurance today cannot cure or relieve.

]]>
https://scubadivetalks.com/reviews-the-economic-mistake-democrats-are-finally-facing/feed/ 0
New drug reduces risk of breast cancer progression https://scubadivetalks.com/new-drug-reduces-risk-of-breast-cancer-progression/ https://scubadivetalks.com/new-drug-reduces-risk-of-breast-cancer-progression/#respond Sun, 19 Sep 2021 01:10:10 +0000 https://scubadivetalks.com/new-drug-reduces-risk-of-breast-cancer-progression/ The trial of a new drug to treat a form of breast cancer has been hailed as “revolutionary,” with the results indicating a strong trend towards improving overall survival. Pharmaceutical company AstraZeneca said Enhertu has shown a 72% reduction in the risk of disease progression or death in women with HER2-positive metastatic breast cancer compared […]]]>

The trial of a new drug to treat a form of breast cancer has been hailed as “revolutionary,” with the results indicating a strong trend towards improving overall survival.

Pharmaceutical company AstraZeneca said Enhertu has shown a 72% reduction in the risk of disease progression or death in women with HER2-positive metastatic breast cancer compared to a different drug.

The results were presented at a presidential symposium at the 2021 Congress of the European Society for Medical Oncology (ESMO).

The trial involving around 500 patients at multiple sites in Asia, Europe, North America, Oceania and South America found that there was “a strong trend in improving overall survival” with Enhertu .

But it was pointed out that this analysis is “not yet mature and is not statistically significant”.

AstraZeneca said that despite initial treatment with trastuzumab and a taxane, people with HER2-positive metastatic breast cancer will often experience disease progression.

The company said almost all patients treated with Enhertu were alive at one year (94.1%) compared to 85.9% of patients treated with trastuzumab emtansine (T-DM1).

Susan Galbraith, Executive Vice President, Oncology R&D, said: “Today’s results are revolutionary.

She said Enhertu tripled progression-free survival as assessed by researchers and provided a disease control rate of over 95% compared to 77% for trastuzumab emtansine.

“These unprecedented data represent a potential paradigm shift in the treatment of HER2-positive metastatic breast cancer and illustrate the potential of Enhertu to transform the lives of more patients in earlier treatment settings,” he said. she adds.

Javier Cortes, of the International Breast Cancer Center in Barcelona, ​​said patients with previously treated HER2-positive metastatic breast cancer will generally experience disease progression within a year with available treatments directed against it. HER2.

He said the “consistent high benefit” seen on the efficacy endpoints and major subgroups of patients receiving Enhertu is “remarkable and supports the potential of Enhertu to become the new standard of care for those who already have been treated for an HER2-positive metastatic breast. Cancer”.

Ken Takeshita, Global Head of R&D at Daiichi Sankyo, said: “This historical data will form the basis of our discussions with global health authorities to potentially offer Enhertu to patients with previously treated HER2-positive metastatic breast cancer. a more effective treatment option as soon as possible. “

For more stories of where you live, visit InYourZone.

]]>
https://scubadivetalks.com/new-drug-reduces-risk-of-breast-cancer-progression/feed/ 0
How House Democrats are expanding Medicare and Medicaid to cut prescription drug costs https://scubadivetalks.com/how-house-democrats-are-expanding-medicare-and-medicaid-to-cut-prescription-drug-costs/ https://scubadivetalks.com/how-house-democrats-are-expanding-medicare-and-medicaid-to-cut-prescription-drug-costs/#respond Sat, 18 Sep 2021 10:32:54 +0000 https://scubadivetalks.com/how-house-democrats-are-expanding-medicare-and-medicaid-to-cut-prescription-drug-costs/ Washington- New Medicare benefits for older Americans, such as dental care. Expand Medicaid eligibility for low-income people in Republican-controlled states who have refused to take this step. And potentially, historic efforts to keep prescription drug prices low – if Democrats in Congress can handle objections from moderates in their party. The sweeping $ 3.5 trillion […]]]>

Washington- New Medicare benefits for older Americans, such as dental care.

Expand Medicaid eligibility for low-income people in Republican-controlled states who have refused to take this step.

And potentially, historic efforts to keep prescription drug prices low – if Democrats in Congress can handle objections from moderates in their party.

The sweeping $ 3.5 trillion budget adjustment package that House Democrats finished sketching out this week will make a big difference to how Americans get medical care.

The proposal stems from President Joe Biden’s “Build Better” policy plan. The Senate is subject to change in the democratic plan of the House. In the Senate, some senators want to change these policies (including providing older people with improved health insurance benefits earlier).

Any plan must pass a procedural summons with the Senator. Senators may decide that the settlement process cannot be used to pass certain clauses of the bill. This procedure allows the bill to pass by a majority vote in an equally divided Senate. In other words, the settlement could reach the president’s office without the support of Republicans.

The medical provisions enshrined in law and their operation are as follows:

Dental, hearing and vision coverage for the elderly

One of the proposals underway in the House of Representatives is to fill the gaps in Medicare coverage. Federal health insurance programs for the elderly and the disabled do not currently cover most dental, hearing or vision care. A service that beneficiaries must currently pay at their own expense or through additional remuneration.

Dentures, hearing aids, eye exams and glasses will be part of the traditional medicare program, as pending legislation adds these benefits.

However, the benefits of dental treatment will not be effective until 2028, a few years after hearing and vision. Some Senate Democrats have objected to the long timeline for integrating dentists into the Medicare program and proposed a voucher program to speed up the transition.

Isn’t that a house bill? Reduced Medicare Eligibility Age

One of the Medicare changes that some Democrats failed was to lower the Medicare enrollment age from the current age of 65 to 60.

That effort was not reflected in House of Representatives legislation, supported by Senator Bernie Sanders, an independent Democrat from Vermont and some college Democrats. It can be added in the Senate, but you might face more serious difficulties in this room.

More access to Medicaid

Another major change is increased health insurance coverage for low-income Americans. This is in part due to the expansion of eligibility in 12 states that have refused to accept federal funding to expand the program.

The 12 states that have refused to meet Medicade eligibility criteria under the Affordable Care Act of 2010 (extended to adults with incomes up to 138% of the poverty level) include Wisconsin, Kansas and Tennessee. Includes North Carolina, Georgia, and Florida. According to the Kaiser Family Foundation.

After 2025, residents of states that have not expanded Medicaid will be able to participate in federally controlled Medicaid programs.

Until the full new federal option comes into effect, the proposal will extend the ACA premium tax credits to people with incomes below the poverty line, making it easier to obtain a claim. health insurance through insurance exchanges.

The proposal also requires the state to begin 30 days before the release of Medicaid compensation for those in prison so that inmates can purchase health insurance upon reintegration into society.

The state should also expand coverage for its Medicaid postnatal program and children’s health insurance one year instead of 60 days after pregnancy ends. The US bailout package, adopted earlier this year, gave the state the flexibility to make changes while regulations demanded.

Controversy over drug price controls

A major challenge in expanding these safety net programs is how to pay for the new costs, part of which is aimed at saving money from overhaul to prescription drug pricing. is.

The proposal allows the federal government to negotiate the prices of hundreds of drugs, including insulin, and penalize drug companies for raising prices faster than inflation. These changes, which are part of another bill, are expected to save HR 3 $ 456 billion over 10 years.

However, the overhaul encountered opposition from a small group of moderate Democrats in the House of Representatives who wanted a narrower approach.

With three Democrats – Congressman Kurt Schrader from Oregon. Scott Peters, California. Kathleen Rice in New York – The Republican Party membership voted against the Energy Commerce Commission’s drug pricing proposal, and the panel got stuck.

The tariff plan was adopted by the Methods and Means Commission, which created another part of the regulatory bill. However, another Democratic vote was lost and D-Fla Rep. Stephanie Murphy opposed it.

“I strongly support many provisions of the Houseways and Means section. Regain better behaviorIn particular, historic provisions to combat the threats of climate change, ”she said in a statement. “But I can’t vote on the bill from the start, because there are also spending and tax provisions that give me a suspension.

“As this process progresses, I am optimistic that the comprehensive settlement package is properly targeted and financially responsible. Pay through tax provisions that promote fairness but do not harm working families. I will do it. “

The battle to keep prescription drug prices low is not yet over. Industry groups representing pharmaceutical companies have been lobbying and promoting proposals for weeks. Some Senate Democrats are skeptical of the drug pricing plans.

How House Democrats are expanding Medicare and Medicaid to cut prescription drug costs

Source link How House Democrats Extend Medicare and Medicaid to Cut Prescription Drug Costs

]]>
https://scubadivetalks.com/how-house-democrats-are-expanding-medicare-and-medicaid-to-cut-prescription-drug-costs/feed/ 0
View the world’s largest pharmaceutical companies https://scubadivetalks.com/view-the-worlds-largest-pharmaceutical-companies/ https://scubadivetalks.com/view-the-worlds-largest-pharmaceutical-companies/#respond Fri, 17 Sep 2021 19:19:19 +0000 https://scubadivetalks.com/view-the-worlds-largest-pharmaceutical-companies/ There is more than 2 billion people of the Generation Z age group around the world. These people, born between 1997 and 2009, make up around 30% of the total world population and it is predicted that by 2025, Gen Z will make up around 27% of the workforce. Unemployment has increased across the board […]]]>

There is more than 2 billion people of the Generation Z age group around the world. These people, born between 1997 and 2009, make up around 30% of the total world population and it is predicted that by 2025, Gen Z will make up around 27% of the workforce.

Unemployment has increased across the board due to the global pandemic, but Gen Z has been hit the hardest. This graph, using data from the OECD, shows the difference between the unemployment rate for Gen Z and the rate for older generations.

Note: The OECD defines “unemployed” as people of legal working age who have no work, are available for work and have taken steps to find a job. The last figure is the number of unemployed as a percentage of the total labor force.

The Generation Gap: Gen Z Unemployment

Compared to their older working-age counterparts, Baby Boomers, Gen X, and Gen Y (Gen Y), the most recent data from 2020 shows Gen Z has an unemployment rate of nearly 2x more in almost all OECD countries.

Country Unemployment rate (Gen Z) Unemployment rate (Millennial, Gen X, Boomer)
Australia 14.3% 5.0%
🇦🇹 Austria 10.5% 4.7%
Belgium 15.3% 4.8%
Canada 20.0% 7.9%
Chile 24.8% 9.6%
🇨🇴 Colombia 27.5% 13.9%
🇨🇿 Czech Republic 8.0% 2.3%
🇩🇰 Denmark 11.5% 4.7%
🇪🇪 Estonia 17.7% 5.9%
Finland 21.0% 6.0%
France 20.1% 6.8%
Germany 6.2% 4.0%
Hungary 12.4% 3.5%
Iceland 11.9% 5.5%
Ireland 15.2% 4.4%
Israel 7.9% 3.7%
Italy 29.1%
Japan 4.5% 2.6%
South Korea 10.5% 3.6%
🇱🇻 Latvia 14.8% 7.7%
🇱🇹 Lithuania 19.5% 7.7%
Luxembourgish 22.4% 5.6%
🇲🇽 Mexico 8.0% 3.8%
Netherlands 9.1% 2.8%
🇳🇿 New Zealand 12.4% 3.3%
🇵🇱 Poland 10.9% 2.6%
Portugal 22.9% 5.9%
🇸🇰 Slovakia 19.3% 6.0%
🇸🇮 Slovenia 14.2% 4.3%
Spain 38.3% 14.0%
Sweden 23.8% 6.4%
Swiss 8.6% 4.3%
UK 13.5% 3.2%
United States 15.1% 7.1%

Note: For the purposes of this article, we are only considering Generation Z of legal working age, that is, those born from 1997 to 2006. Others, Baby Boomers, Generation X and millennials, are those born between 1946 and 1996.

The timing for the younger working generation couldn’t be worse. Gen Z are just starting to graduate from college and high school, and are starting to look for work and careers.

Gen Z are also an over-represented age group in service industries like restaurants and travel, which have been equally badly hit by the pandemic. In the United States, for example, approximately 25% of young people work in the hotel and leisure sectors. Between February and May 2020 alone, employment in these sectors fell by 41%.

Countries like Spain face some of the biggest headwinds among OECD countries. The country already has a high unemployment rate for 25-74 year olds, at 14%. But Gen Z’s unemployment rate is more than double, at over 38%.

Implications for the Future

While it may be true throughout history that this age group is often less employed than older cohorts, the share of the workforce held by 15-24 year olds has declined significantly in 2020. .

Note: This graph represents data for G7 countries.

When it comes to their future employment prospects, some economists anticipate what they call “scars.” Due to longer spells of unemployment, Gen Z will miss years of education to gain experience and training. This can impact them later in life as their ability to move up the career ladder will be affected.

A slower start can also affect income. One study found that long spells of youth unemployment can reduce lifetime income by 2%. Finally, it is also postulated that with the current economic situation, Gen Z can accept lower paying jobs, which puts them on a path of comparatively lower income over their lifetime.

Overall, the current Gen Z unemployment rate has many implications for the future. Often times, getting your foot in the door after college or high school is one of the hardest steps in starting a career. Once you’re in, you gain the much coveted knowledge, skills, and experience needed to move forward.

Are the children okay?

One bright spot for Gen Z is that they have been shown to be more risk averse and financially aware than other generations, and were even before COVID-19. Many of them were children during the 2008 recession and have become very cautious as a result.

They are also the first digital generation, the first to grow up with no memory of before the Internet. In addition, they have been called the first generation of the world. This could mean that they are paving the way for place-independent careers, creating innovative income streams, and finding new ways to define work.

]]>
https://scubadivetalks.com/view-the-worlds-largest-pharmaceutical-companies/feed/ 0
InMed Pharmaceuticals and BayMedica participate in Tribe Public webinar “Accelerating the Commercialization of Rare Cannabinoids” https://scubadivetalks.com/inmed-pharmaceuticals-and-baymedica-participate-in-tribe-public-webinar-accelerating-the-commercialization-of-rare-cannabinoids/ https://scubadivetalks.com/inmed-pharmaceuticals-and-baymedica-participate-in-tribe-public-webinar-accelerating-the-commercialization-of-rare-cannabinoids/#respond Fri, 17 Sep 2021 11:30:00 +0000 https://scubadivetalks.com/inmed-pharmaceuticals-and-baymedica-participate-in-tribe-public-webinar-accelerating-the-commercialization-of-rare-cannabinoids/ Registration for the September 21, 2021 event is now open VANCOUVER, British Columbia, September 17, 2021 (GLOBE NEWSWIRE) – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacture and clinical development of rare cannabinoids, today announces that Eric A. Adams, CEO of InMed, and Shane Johnson, co -Founder of BayMedica […]]]>

Registration for the September 21, 2021 event is now open

VANCOUVER, British Columbia, September 17, 2021 (GLOBE NEWSWIRE) – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacture and clinical development of rare cannabinoids, today announces that Eric A. Adams, CEO of InMed, and Shane Johnson, co -Founder of BayMedica Inc (“BayMedica”) will be presenting at Tribe Public’s webinar and Q&A event titled “Accelerating the Commercialization of Rare Cannabinoids”. The event is scheduled to begin at 8:30 a.m. Pacific Time and 11:30 a.m. Eastern Time on September 21, 2021.

To register for the free event based on the ZOOM webinar, please visit Tribe Public LLC at INM.TribePublic.com. Once registered, attendees can start directing their questions to the management of InMed and BayMedica at Tribe Public at research@tribepublic.com or share their questions via the ZOOM chat feature during the event. Tribe Public Managing Member John F. Heerdink, Jr. will host the event and forward all questions to management.

On September 13, 2021, InMed announced that it had entered into a definitive agreement (“Definitive Agreement”) to acquire BayMedica, a private company based in the United States and specializing in the manufacture and marketing of rare cannabinoids. The definitive agreement follows a pre-signed letter of intent (the “LOI”) announced on June 29, 2021. The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks. Upon closing, InMed will become a global leader in the manufacture of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches. InMed’s proprietary cannabinoid manufacturing process, IntegraSyn ™, combined with BayMedica’s synthetic biology and chemical synthesis capabilities, will provide InMed with complete manufacturing flexibility to select the most suitable and cost effective method based on the cannabinoid. target and quality specifications appropriate for the desired market segment. . Along with the manufacture of cannabinoids, the combined company will continue to explore the therapeutic potential of cannabinoids and novel cannabinoid analogues for pharmaceutical drug development, as well as to expand commercial sales of rare cannabinoids to the healthcare and healthcare industry. consumer welfare.

About InMed
InMed Pharmaceuticals is a clinical-stage company developing a pipeline of rare cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), and developing IntegraSyn ™ to produce pharmaceutical grade cannabinoids. The Company is dedicated to providing new therapeutic alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

About Tribe Public LLC
Tribe Public LLC is a San Francisco, California-based organization that hosts free webinars and meetings around the world in the United States. & financial organizations looking to increase awareness of their products, progress and plans. Members of the tribe primarily include institutions, Family Offices, portfolio managers, registered investment advisers, accredited investors, sell-side analysts and members of the media. Tribe members are encouraged to express their interest in the speakers on the tribe’s public website through the FREE tribe “wishlist” process. Visit the Tribe Public website http://www.tribepublic.com/ to join the tribe and express your interests today

Investor contact:
Colin Clancy
Senior Director, Investor Relations
T: +1 604 416 0999
E: cclancy@inmedpharma.com

Edison Group:
Joe Green / Yonker Wool
T: + 1.646.653.7030 / + 1.646.653.7035
E: jgreen@edisongroup.com / lyonker@edisongroup.com

Caution regarding forward-looking information:

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based on management’s current expectations, inherently involve many risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements..

With respect to the forward-looking information contained in this press release, InMed has made numerous assumptions regarding, among others: the presentation during the Tribe Public webinar presentation; the proposed transaction with BayMedica occurring on the terms advertised, if at all; the completion of the proposed transaction with BayMedica and the expected results and potential of the activities of BayMedica and the combination of the activities of BayMedica with those of InMed; become a world leader in the manufacture of rare cannabinoids; continued stability of the economy and the market; offer new therapeutic alternatives to patients who could benefit from cannabinoid-based pharmaceutical drugs; to move IntegraSyn ™ to commercial scale production; develop IntegraSyn ™ to produce pharmaceutical grade cannabinoids; and the development of a pipeline of cannabinoid-based pharmaceutical drug candidates. Although InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant commercial, economic, competitive, market and social uncertainties and contingencies.

In addition, there are known and unknown risk factors which could cause InMed’s actual results, performances or achievements to differ materially from future results, performances or achievements expressed or implied by the forward-looking information contained in the this document. Known risk factors include, but are not limited to: regulatory filings may not be filed or approved in a timely manner, if at all. A more complete discussion of the risks and uncertainties facing InMed’s stand-alone activities is disclosed in the documents filed by InMed with the Security and Exchange Commission and in the most recent Annual Information Form and other continuing information filed with the Canadian securities regulators. Securities on SEDAR at www.sedar. com.

All forward-looking information contained in this document is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update such forward-looking information or to publicly announce the result of any revision of any of the information. forward-looking statements contained herein. to reflect future results, events or developments, except as required by law.

]]>
https://scubadivetalks.com/inmed-pharmaceuticals-and-baymedica-participate-in-tribe-public-webinar-accelerating-the-commercialization-of-rare-cannabinoids/feed/ 0
Takeda Therapy Quickly Gets FDA Green Light for Lung Cancers with Rare Genetic Signature https://scubadivetalks.com/takeda-therapy-quickly-gets-fda-green-light-for-lung-cancers-with-rare-genetic-signature/ https://scubadivetalks.com/takeda-therapy-quickly-gets-fda-green-light-for-lung-cancers-with-rare-genetic-signature/#respond Thu, 16 Sep 2021 17:24:41 +0000 https://scubadivetalks.com/takeda-therapy-quickly-gets-fda-green-light-for-lung-cancers-with-rare-genetic-signature/ Takeda Pharmaceutical’s anticancer drug portfolio added another FDA-approved product, a targeted therapy that treats tumors with a rare genetic signature. The FDA has approved Takeda’s drug, mobocertinib, for adults whose non-small cell lung cancer has spread, locally or to other parts of the body, after treatment with chemotherapy. The cancer should be characterized by an […]]]>

Takeda Pharmaceutical’s anticancer drug portfolio added another FDA-approved product, a targeted therapy that treats tumors with a rare genetic signature.

The FDA has approved Takeda’s drug, mobocertinib, for adults whose non-small cell lung cancer has spread, locally or to other parts of the body, after treatment with chemotherapy. The cancer should be characterized by an insertion mutation at exon 20 of the epidermal growth factor receptor (EGFR), a protein involved in cell signaling. EGFR mutations contribute to the rapid cell growth of tumors.

Non-small cell lung cancer is the most common form of lung cancer, accounting for about 85% of all new cases diagnosed each year. However, EGFR exon 20 insertion mutations are rare, accounting for approximately 1% to 2% of cases. Currently available anticancer drugs that target EGFR do not work against EGFR exon 20 insertion mutations.

The first drug that targets this mutation, Rybrevant from Johnson & Johnson, received the regulatory green light in May. But this bispecific antibody is administered by infusion. The drug Takeda is a small molecule that comes in a capsule form, making it the first oral treatment for this particular genetic mutation. Takeda will market its new cancer drug under the name “Exkivity”.

The FDA’s approval of Exkivity was based on the results of an open-label phase 1/2 study that evaluated the drug Takeda in 114 patients whose cancer carried the EGFR exon 20 insertion mutation. . The patients took the drug once a day. The main objective of the clinical trial was to measure the overall response rate and the duration of response.

The FDA said the overall response rate was 28%; the median duration of this response was 17.5 months. The results also showed that the overall survival of the patients was a median of 24 months. Takeda presented the updated study results at the American Society of Clinical Oncology annual conference in May.

The most common side effects reported in the study included diarrhea, rash, nausea, inflammation and pain in the mouth, and vomiting. The drug label has a black box warning that alerts doctors and patients that the drug can cause a heart rhythm problem that could become fatal. Patients should be monitored for heart rhythm problems while taking the medicine.

EGFR exon 20 insertion mutation should be detected by companion diagnosis. Along with Exkivity’s regulatory approval, the FDA also approved a Thermo Fisher Scientific test that identifies the mutation.

Approval for the drug Takeda came earlier than expected. The FDA’s target date for a decision was October 26. The decision was expedited approval based on less evidence than is typically required for a drug review. Such approvals force pharmaceutical companies to conduct post-market studies to confirm efficacy, continuing to show that a drug’s benefits outweigh the safety risks.

Photo: Scott Eisen / Bloomberg, via Getty Images

]]>
https://scubadivetalks.com/takeda-therapy-quickly-gets-fda-green-light-for-lung-cancers-with-rare-genetic-signature/feed/ 0